Literature DB >> 23619390

Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.

Karim A Touijer1, Clarisse R Mazzola, Daniel D Sjoberg, Peter T Scardino, James A Eastham.   

Abstract

BACKGROUND: The presence of lymph node metastasis (LNM) at radical prostatectomy (RP) is associated with poor outcome, and optimal treatment remains undefined. An understanding of the natural history of node-positive prostate cancer (PCa) and identifying prognostic factors is needed.
OBJECTIVE: To assess outcomes for patients with LNM treated with RP and lymph node dissection (LND) alone. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from a consecutive cohort of 369 men with LNM treated at a single institution from 1988 to 2010. INTERVENTION: RP and extended LND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Our primary aim was to model overall survival, PCa-specific survival, metastasis-free progression, and freedom from biochemical recurrence (BCR). We used univariate Cox proportional hazard regression models for survival outcomes. Multivariable Cox proportional hazard regression models were used for freedom from metastasis and freedom from BCR, with prostate-specific antigen, Gleason score, extraprostatic extension, seminal vesical invasion, surgical margin status, and number of positive nodes as predictors. RESULTS AND LIMITATIONS: Sixty-four patients with LNM died, 37 from disease. Seventy patients developed metastasis, and 201 experienced BCR. The predicted 10-yr overall survival and cancer-specific survival were 60% (95% confidence interval [CI], 49-69) and 72% (95% CI, 61-80), respectively. The 10-yr probability of freedom from distant metastasis and freedom from BCR were 65% (95% CI, 56-73) and 28% (95% CI, 21-36), respectively. Higher pathologic Gleason score (>7 compared with ≤ 7; hazard ratio [HR]: 2.23; 95% CI, 1.64-3.04; p < 0.0001) and three or more positive lymph nodes (HR: 2.61; 95% CI, 1.81-3.76; p < 0.0001) were significantly associated with increased risk of BCR on multivariable analysis. The retrospective nature and single-center source of data are study limitations.
CONCLUSIONS: A considerable subset of men with LNM remained free of disease 10 yr after RP and extended LND alone. Patients with pathologic Gleason score <8 and low nodal metastatic burden represent a favorable group. Our data confirm prior findings and support a plea for risk subclassification for patients with LNM.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biochemical recurrence; Lymph node dissection; Lymph node metastasis; Prognosis; Prostate; Prostate cancer; Radical prostatectomy; Staging

Mesh:

Substances:

Year:  2013        PMID: 23619390     DOI: 10.1016/j.eururo.2013.03.053

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  37 in total

1.  Prostate cancer: lymph node metastases: not always the same prognosis.

Authors:  Riccardo Schiavina; Eugenio Brunocilla
Journal:  Nat Rev Urol       Date:  2013-06-11       Impact factor: 14.432

2.  A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.

Authors:  Tian-Bao Huang; Chuan-Peng Dong; Guang-Chen Zhou; Sheng-Ming Lu; Yang Luan; Xiao Gu; Lei Liu; Xue-Fei Ding
Journal:  Int Urol Nephrol       Date:  2017-02-10       Impact factor: 2.370

Review 3.  High-risk prostate cancer-classification and therapy.

Authors:  Albert J Chang; Karen A Autio; Mack Roach; Howard I Scher
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

4.  Sentinel lymph node dissection in prostate cancer using superparamagnetic particles of iron oxide: early clinical experience.

Authors:  M Staník; D Macík; I Čapák; N Marečková; E Lžíčařová; J Doležel
Journal:  Int Urol Nephrol       Date:  2018-06-15       Impact factor: 2.370

5.  Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy.

Authors:  Piotr Zareba; James Eastham; Peter T Scardino; Karim Touijer
Journal:  J Urol       Date:  2017-06-15       Impact factor: 7.450

6.  Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts.

Authors:  Hesham Elghazaly; Nicolas Mottet; Jorge Garcia; Stephane Oudard; Mack Roach; Claude Abbou; Axel Merseburger; Amr Emara; Samir Shehata; Hesham Tawfik; Ola Khorshid; Ahmed Selim; Akram Assem; Khalid Abdelkarim; Lobna Ezz El-Arab; Shouki Bazarbashi; Abbass Omar; Hesham Elwakil; Mohamed Elashry; Mohamed Abou ElFotouh; Tarek Osman; Mai Ezz El Din
Journal:  World J Urol       Date:  2020-07-08       Impact factor: 4.226

7.  Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.

Authors:  Philipp Mandel; Clemens Rosenbaum; Raisa S Pompe; Thomas Steuber; Georg Salomon; Felix K Chun; Markus Graefen; Hartwig Huland; Derya Tilki
Journal:  World J Urol       Date:  2017-08-21       Impact factor: 4.226

Review 8.  Prostate Cancer Academy 2017 Summaries.

Authors:  Dmitry Volkin
Journal:  Rev Urol       Date:  2017

9.  Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy.

Authors:  Avinash Chenam; Jaspreet S Parihar; Nora Ruel; Sumanta Pal; Yvonne Avila; Jonathan Yamzon; Clayton Lau; Bertram Yuh
Journal:  J Robot Surg       Date:  2017-09-13

10.  Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.

Authors:  J W Yaxley; J Dagher; B Delahunt; L Egevad; J Srigley; H Samaratunga
Journal:  World J Urol       Date:  2017-11-07       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.